Harbour BioMed and Sinopharm form a biologics R&D consortium spanning antibody discovery, clinical development, manufacturing and commercialisation.
Eli Lilly’s retatrutide delivered up to 22.6% weight loss in two Phase 3 trials as a 2027 FDA filing moves closer.
SimBioSys and Ferrum Health bring FDA-cleared TumorSight Viz to Ferrum’s Model Hub, targeting scalable breast surgery AI deployment.
Precision Diabetes and Nagase Diagnostics target wider U.S. access for Lucica, an FDA-cleared assay for two-to-three-week glycemic monitoring.
See how Evoworks Bio’s BARDA-backed EvoNode project could test faster, modular antibody production for United States health security.
Canton Strategic sells Gravitas Life Sciences for a $3.5 million seller note, sharpening its Canton Network focus as biotech risks shift.
Accord BioPharma launches Osvyrti and Jubereq as interchangeable denosumab biosimilars, testing price, payer access and provider adoption.
Johnson & Johnson’s Tecvayli-Talvey regimen cut progression risk by 89% in MonumenTAL-6. See what the topline data still must prove.
AnX Robotica launches NaviCONNECT to bring NaviCam capsule studies, AI-assisted review and multi-site workflows into a secure cloud platform.
argenx is buying Forte Biosciences for $2.2bn to secure FB102. See why early vitiligo and celiac data make Phase 2 execution decisive.